Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Clin. Cancer Res., May;18(9):2668-78 (2012)
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gynecol. Oncol., Dec;123(3):479-85 (2011)
Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer.
J Support Oncol., 8(6):252-8 (2010 Nov-Dec)
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Clin. Cancer Res., Nov;16(21):5320-8 (2010)
Cervical cancer: prevention, diagnosis, and therapeutics.
CA Cancer J Clin., 51(2):92-114; quiz 115-8 (2001 Mar-Apr)
Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
Gynecol. Oncol., Sep;74(3):448-55 (1999)
Epidemiology and biology of cervical cancer.
Semin Surg Oncol., 16(3):203-11 (1999 Apr-May)
p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Gynecol. Oncol., Jul;66(1):94-102 (1997)
In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
Gynecol. Oncol., Jan;64(1):18-25 (1997)
Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines.
Gynecol. Oncol., Oct;59(1):87-92 (1995)
The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society.
Cancer., Sep;76(6):1096-103 (1995)
Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia.
Gynecol. Oncol., Mar;52(3):373-8 (1994)